Cell & Gene: The Podcast

27:58

Structuring CGT Deals for the Long Term with Troutman...

Cell & Gene: The Podcast ·

2026/09/24

We love to hear from our listeners. Send us a message. In episode 138 of Cell & Gene: The Podcast, EA Weeks, J.D., Ph.D., Counsel at Troutman Pepper Locke talks to Host Erin Harris about the deal terms that matter most in CGT, including IP ownership, manufacturing capacity, CMC milestones, data rights, tech transfer, and more. They also discuss planning for what happens when a partnership does not go as expected. Subscribe to the podcast! Apple | Spotify | YouTube Visit ...

en

18:47

Shaping Drug Development by Starting with the Disease...

Cell & Gene: The Podcast ·

2026/09/10

We love to hear from our listeners. Send us a message. In episode 137 of Cell & Gene: The Podcast, Host Erin Harris talks with Sylke Poehling, Ph.D., SVP and Global Head: Therapeutic Modalities, pRED; Roche Gene Therapy Center of Excellence about how the company selects the optimal modality by starting with disease biology. Dr. Poehling explains how an integrated Center of Excellence brings together discovery, safety, manufacturing, and development expertise to reduce technical risk and a...

en

40:25

Why Autoimmune CAR T Needs a New Patient-Centered...

Cell & Gene: The Podcast ·

2026/08/27

We love to hear from our listeners. Send us a message. On episode 136 of Cell & Gene: The Podcast, Host Erin Harris welcomes back Dr. Panteli Theocharous, FIBMS, M.S., Ph.D., FRCPath to discuss why autoimmune CAR T is moving rapidly from an emerging concept toward a potentially transformative treatment approach. They talk about the very different benefit-risk calculus in autoimmune disease compared with oncology, the patient and caregiver burden of conditioning, apheresis and long-term mo...

en

16:18

Reimagining Solid Tumor Immunotherapy Through...

Cell & Gene: The Podcast ·

2026/08/13

We love to hear from our listeners. Send us a message. In Episode 135 of Cell & Gene: The Podcast, Host Erin Harris talks to Sonal Gupta, MD, PhD, Chief Medical Officer of CoRegen, about the company's novel approach to treating solid tumors by engineering regulatory T cells (Tregs) rather than conventional effector immune cells. Dr. Gupta explains how CoRegen's investigational cell therapy, CRG150, targets the upstream regulator SRC3 to simultaneously influence multiple immune checkpoint ...

en

18:05

Rewriting the Playbook for Stargardt Disease with...

Cell & Gene: The Podcast ·

2026/07/30

We love to hear from our listeners. Send us a message. Episode 134 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Shannon Boye, PhD, Founder and CSO of Atsena Therapeutics. Dr. Boye shares how the company is approaching Stargardt disease with a differentiated gene therapy strategy built around delivery, dual-vector design, and a disciplined go/no-go framework. Their conversation also explores what Atsena’s broader clinical experience is teaching the team as it adva...

en

18:03

How Precision Oncology Is Redefining Cancer Drug...

Cell & Gene: The Podcast ·

2026/07/16

We love to hear from our listeners. Send us a message. Episode 133 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Aprea Therapeutics' CEO, Dr. Oren Gilad. They cover the evolution of precision oncology, the science of synthetic lethality, and how Aprea is developing next-generation therapies that target cancer's unique genetic vulnerabilities while improving safety and efficacy. Dr. Gilad also shares insights into biomarker-driven drug development, where precision ...

en

22:57

Exploring Dendritic Cell Therapy for Solid Tumors...

Cell & Gene: The Podcast ·

2026/07/02

We love to hear from our listeners. Send us a message. Episode 132 of Cell & Gene: The Podcast features Host, Erin Harris' conversation with Diakonos Oncology's President and COO, Jay Hartenbach. Together, they explore how the company is advancing a patient-derived dendritic cell therapy designed to generate a stronger immune response against difficult-to-treat solid tumors, including glioblastoma, pancreatic cancer, and refractory melanoma. Their discussion also covers early clinical sig...

en

85:47

Cell & Gene: The Podcast Presents: Better Biopharma’s...

Cell & Gene: The Podcast ·

2026/06/18

We love to hear from our listeners. Send us a message. For episode 131 of Cell & Gene: The Podcast, we’re sharing a recent "Better Biopharma" roundtable that Erin Harris had the opportunity to join alongside her Life Science Connect editorial colleagues. Hosted by Tyler Menichiello, this conversation brings together chief editors from across the Life Science Connect network to take a midyear look at what’s shaping the pharmaceutical and biotech landscape in 2026. Featuring perspectives fr...

en

18:11

Why In Vivo Therapies Are Moving Toward the Clinic...

Cell & Gene: The Podcast ·

2026/06/12

We love to hear from our listeners. Send us a message. In Episode 3 of our in vivo-focused special series of Cell & Gene: The Podcast, Ascidian Therapeutics' Founder, President, and CEO Mike Ehlers, M.D., Ph.D., explains how the company is advancing a new class of genetic medicines built on RNA exon editing to durably correct disease at the transcript level without permanently altering DNA. He also shares why in vivo therapies still need to prove precision, durability, and predictability ...

en

18:11

Reimagining In Vivo Gene Editing Through Base Editing...

Cell & Gene: The Podcast ·

2026/06/05

We love to hear from our listeners. Send us a message. In episode 2 of this four-part in vivo-focused special series of Cell & Gene: The Podcast, Host Erin Harris sits down with Gopi Shanker, Ph.D., Chief Scientific Officer at Beam Therapeutics, for an in-depth conversation on the rapidly evolving landscape of in vivo gene editing and precision genetic medicines. Dr. Shanker discusses how next-generation base editing technologies are advancing beyond traditional CRISPR approaches by enabl...

en

22:30

Advancing CAR T for Drug-Free Remission in Autoimmune...

Cell & Gene: The Podcast ·

2026/06/04

We love to hear from our listeners. Send us a message. In episode 130 of Cell & Gene: The Podcast, Dr. Naji Gehchan, Chief Medical and Development Officer at Kyverna Therapeutics, joins Host Erin Harris to outline the company’s mission to apply CAR T-cell therapy beyond oncology to treat severe autoimmune diseases, highlighting promising Phase 2 data from its investigational therapy, Miv-cel, in stiff person syndrome (SPS). Dr. Gehchan explains that Miv-cel works by deeply depleting patho...

en

31:43

The Future of In Vivo Gene Editing and Clinical...

Cell & Gene: The Podcast ·

2026/05/29

We love to hear from our listeners. Send us a message. This is Episode 1 of a four-episode in vivo-focused special series of Cell & Gene: The Podcast. Host Erin Harris speaks with Cassie Gorsuch, Ph.D., CSO at Precision Biosciences, about the rapid evolution of in vivo gene editing and the scientific, translational, and regulatory hurdles shaping the field. Dr. Gorsuch discusses how Precision Biosciences approaches in vivo therapeutic development through its Arcus platform, with programs ...

en

18:13

Redefining CAR-T Timing and Patient Access with...

Cell & Gene: The Podcast ·

2026/05/21

We love to hear from our listeners. Send us a message. In episode 129 of Cell & Gene: The Podcast, Host Erin Harris reconnects with Zachary Roberts, M.D., Ph.D., EVP of Research & Development and Chief Medical Officer at Allogene Therapeutics, to explore how allogeneic CAR-T is evolving from a scalability promise into an earlier-line, potentially curative intervention. Their conversation centers on the ALPHA3 trial, where MRD-guided treatment is redefining when and how CAR-T can be de...

en

43:42

Building Integrated cGMP Systems for Autologous Cell...

Cell & Gene: The Podcast ·

2026/05/07

We love to hear from our listeners. Send us a message. In episode 128, Host Erin Harris talks to Tatyana Matveeva, Ph.D., Director of cGMP Operations at George A. "Doc" Lopez, MD Laboratory for Regenerative Cell Therapy, Harvard Medical School and Massachusetts General Hospital, about leading cGMP operations within an integrated ecosystem, where manufacturing, research, and neurosurgery coexist. Dr. Matveeva highlights key operational challenges in scaling autologous therapies, pa...

en

23:27

Rewriting Disease Biology Through LSD1 Inhibition...

Cell & Gene: The Podcast ·

2026/04/23

We love to hear from our listeners. Send us a message. On Episode 127 of Cell & Gene: The Podcast, Carlos Buesa, Ph.D., Founder and Chairman of the Board at Oryzon talks to Host Erin Harris about how targeting LSD1 is unlocking new treatment approaches across oncology, CNS disorders, and sickle cell disease, with promising early clinical data and a strategy grounded in precision epigenetics. Subscribe to the podcast! Apple | Spotify | YouTube Visit my website: Cell &...

en

20:46

Advancing Early Detection in Rare Cancers with...

Cell & Gene: The Podcast ·

2026/04/09

We love to hear from our listeners. Send us a message. On episode 126 of Cell & Gene: The Podcast, Host Erin Harris welcomes Catriona Jamieson, M.D., Ph.D, Director of the UC San Diego Sanford Stem Cell Institute and Professor of Medicine at the School of Medicine. They explore how shifting the medical mindset from “common horses” to rare “zebras” is unlocking earlier detection and more effective treatment of diseases like myelofibrosis. Dr. Jamieson explains how subtle, often overlooked ...

en

27:18

Regulatory Flexibility in CGT: Key Shifts and...

Cell & Gene: The Podcast ·

2026/03/26

We love to hear from our listeners. Send us a message. On episode 125 of Cell & Gene: The Podcast, Host Erin Harris talks to Halloran Consulting Group's Monika Swietlicka to discuss how the FDA is increasing flexibility in cell and gene therapy development without lowering evidentiary standards, emphasizing a risk-based, holistic approach. They also explore what this means for developers, from platform strategies and global regulatory divergence to the growing role of patient advocacy and...

en

28:04

Scaling CRISPR for Rare Disease with Aurora...

Cell & Gene: The Podcast ·

2026/03/12

We love to hear from our listeners. Send us a message. On episode 124 of Cell & Gene: The Podcast, Aurora Therapeutics' CEO Dr. Edward Kaye discusses the company’s strategy for translating CRISPR gene editing into scalable, commercially viable medicines for rare diseases. Aurora is initially targeting phenylketonuria (PKU) using a platform approach that leverages shared components, such as lipid nanoparticles and base editors, while customizing guide RNAs for specific mutations. Dr. Kaye ...

en

34:24

Simplifying Friction in Cell Therapy Clinical Trials...

Cell & Gene: The Podcast ·

2026/02/26

We love to hear from our listeners. Send us a message. In episode 123 of Cell & Gene: The Podcast, Host Erin Harris talks to Dr. Panteli Theocharous, FIBMS, M.S., Ph.D., FRCPath, about the patient journey in cell therapy trials. They pinpoint key friction points, such as delayed referrals, unpredictable vein-to-vein timelines, and burdensome long-term follow-up, while sharing actionable strategies for simplification. These strategies range from upstream trial design and streamlined consen...

en

14:20

Inside a Breakthrough HER2 Immunotherapy for PMO with...

Cell & Gene: The Podcast ·

2026/02/12

We love to hear from our listeners. Send us a message. In episode 122 of Cell & Gene: The Podcast, Host Erin Harris talks to Paul Romness, CEO of OS Therapies, to learn the company’s mission to address the severe unmet need in pulmonary metastatic osteosarcoma (PMO), a rare pediatric cancer with no established standard of care once it metastasizes. Romness explains how OS Therapies’ off-the-shelf HER2-targeted immunotherapy aims to significantly improve outcomes by stimulating a robust im...

en

All Episodes

Similar Podcasts

The Deep Dive Lab: Unraveling Materials Science

Son Hoang

New Books in Political Science

New Books Network

Station 151

Pale Matter | Realm

Beyond the Divide

Koala Moon

StarTalk with Neil deGrasse Tyson

Neil deGrasse Tyson